Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Esophageal Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
28 drugs · 167 active trials
6 drugs · 136 active trials
6 drugs · 74 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab | Approved | Phase 3 | 24 | 15 | 5 | 62 | 1 | US | Sep 4, 2014 | 2014-10 |
| Nivolumab | Approved | Phase 3 | 23 | 12 | 9 | 37 | 4 | US | Dec 22, 2014 | Aug 17, 2015 |
| Tislelizumab | Approved | Phase 3 | 20 | 12 | 8 | 34 | 3 | US | Mar 13, 2024 | Jul 18, 2017 |
| Ipilimumab | Approved | Phase 3 | 4 | 2 | 1 | 8 | 1 | US | Mar 25, 2011 | Oct 12, 2016 |
| Zanidatamab | Approved | Phase 3 | 3 | 2 | 1 | 3 | 2 | US | Nov 20, 2024 | Dec 2, 2021 |
| Porfimer | Approved | Phase 2 | 0 | 0 | 0 | 1 | 2 | US | Dec 27, 1995 | 1995-10 |
| Paclitaxel | Phase 4 | Phase 4 | 36 | 17 | 30 | 119 | 0 | — | — | 1995-10 |
| Cisplatin | Phase 4 | Phase 4 | 28 | 16 | 37 | 139 | 0 | — | — | 1992-07 |
| Fluorouracil | Phase 4 | Phase 4 | 26 | 15 | 28 | 118 | 0 | — | — | 1992-07 |
| Oxaliplatin | Phase 4 | Phase 4 | 20 | 11 | 14 | 74 | 0 | — | — | 1998-04 |
| Leucovorin | Phase 4 | Phase 4 | 15 | 8 | 10 | 48 | 0 | — | — | 1998-08 |
| Irinotecan | Phase 4 | Phase 4 | 11 | 6 | 13 | 65 | 0 | — | — | 1997-06 |
| Carboplatin | Phase 3 | Phase 3 | 25 | 9 | 4 | 63 | 0 | — | — | Sep 3, 1999 |
| Capecitabine | Phase 3 | Phase 3 | 16 | 10 | 13 | 47 | 0 | — | — | 2001-07 |
| Chemotherapy | Phase 3 | Phase 3 | 16 | 11 | 6 | 29 | 0 | — | — | 1995-06 |
| Nab-paclitaxel | Phase 3 | Phase 3 | 14 | 9 | 1 | 27 | 0 | — | — | 2014-01 |
| Toripalimab | Phase 3 | Phase 3 | 12 | 6 | 3 | 26 | 0 | — | — | Nov 21, 2018 |
| Docetaxel | Phase 3 | Phase 3 | 11 | 7 | 15 | 56 | 0 | — | — | 1997-08 |
| Sintilimab | Phase 3 | Phase 3 | 10 | 7 | 5 | 19 | 0 | — | — | May 10, 2017 |
| Immunotherapy | Phase 3 | Phase 3 | 8 | 8 | 3 | 8 | 0 | — | — | Jan 1, 2002 |
| Durvalumab | Phase 3 | Phase 3 | 7 | 3 | 1 | 17 | 0 | — | — | 2016-02 |
| Trastuzumab | Phase 3 | Phase 3 | 7 | 4 | 4 | 17 | 0 | — | — | 2011-02 |
| Camrelizumab | Phase 3 | Phase 3 | 6 | 2 | 5 | 27 | 0 | — | — | May 5, 2017 |
| Nimotuzumab | Phase 3 | Phase 3 | 5 | 4 | 5 | 17 | 0 | — | — | Jan 1, 2002 |
| Ramucirumab | Phase 3 | Phase 3 | 5 | 3 | 2 | 11 | 0 | — | — | 2011-04 |
| Lenvatinib | Phase 3 | Phase 3 | 4 | 1 | 1 | 6 | 0 | — | — | Jul 28, 2021 |
| Levoleucovorin | Phase 3 | Phase 3 | 4 | 2 | 3 | 6 | 0 | — | — | Feb 28, 2020 |
| Cetuximab | Phase 3 | Phase 3 | 3 | 2 | 3 | 27 | 0 | — | — | 2004-08 |
| Atezolizumab | Phase 3 | Phase 3 | 3 | 0 | 2 | 9 | 0 | — | — | Jun 28, 2017 |
| Carboplatin/Paclitaxel Regimen | Phase 3 | Phase 3 | 3 | 1 | 1 | 6 | 0 | — | — | Apr 28, 2016 |
| Tegafur | Phase 3 | Phase 3 | 3 | 3 | 1 | 4 | 0 | — | — | Jul 1, 2022 |
| Pertuzumab | Phase 3 | Phase 3 | 2 | 1 | 1 | 2 | 0 | — | — | Aug 17, 2015 |
| Aspirin | Phase 3 | Phase 3 | 1 | 0 | 2 | 4 | 0 | — | — | Mar 10, 2005 |
| Tucatinib | Phase 3 | Phase 3 | 1 | 0 | 1 | 2 | 0 | — | — | Sep 15, 2020 |
| Zolbetuximab | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Feb 3, 2026 |
| Panitumumab | Phase 3 | Phase 3 | 0 | 0 | 1 | 9 | 0 | — | — | 2000-04 |
| Epirubicin | Phase 3 | Phase 3 | 0 | 0 | 2 | 8 | 0 | — | — | 2001-07 |
| Paclitaxel Liposome | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | 2000-12 |
| Vinorelbine | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2000-06 |
| Adjuvant Chemotherapy | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2010-04 |
| Adebrelimab | Phase 2 | Phase 2 | 9 | 5 | 0 | 12 | 0 | — | — | 2018-11 |
| Bevacizumab | Phase 2 | Phase 2 | 4 | 4 | 0 | 14 | 0 | — | — | 2004-08 |
| Serplulimab | Phase 2 | Phase 2 | 4 | 3 | 0 | 4 | 0 | — | — | Dec 1, 2023 |
| FOLFOX Regimen | Phase 2 | Phase 2 | 3 | 1 | 0 | 8 | 0 | — | — | 2000-02 |
| Tremelimumab | Phase 2 | Phase 2 | 3 | 2 | 0 | 7 | 0 | — | — | Apr 28, 2016 |
| Futibatinib | Phase 2 | Phase 2 | 3 | 1 | 0 | 3 | 0 | — | — | Jun 1, 2021 |
| Gemcitabine | Phase 2 | Phase 2 | 2 | 1 | 0 | 8 | 0 | — | — | 1998-08 |
| Fludarabine | Phase 2 | Phase 2 | 2 | 1 | 0 | 5 | 0 | — | — | 2015-04 |
| Cabozantinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | Oct 22, 2018 |
| Palbociclib | Phase 2 | Phase 2 | 2 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.